| scholarly article | Q13442814 |
| P50 | author | Roy S. Herbst | Q89006575 |
| George R Blumenschein | Q94702986 | ||
| Frank V Fossella | Q94703174 | ||
| Maria Werner-Wasik | Q63151288 | ||
| Ritsuko Komaki | Q64585410 | ||
| P2093 | author name string | Walter J Curran | |
| Francisco Robert | |||
| Rebecca Paulus | |||
| Hak Choy | |||
| Philip O Doescher | |||
| P2860 | cites work | Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer | Q73181790 |
| In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody | Q73483324 | ||
| Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms | Q73803447 | ||
| Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation | Q73886698 | ||
| Cancer statistics, 2008 | Q27860585 | ||
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship | Q28278682 | ||
| Erlotinib in previously treated non-small-cell lung cancer | Q29547546 | ||
| Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck | Q29619277 | ||
| Carboplatin dosage: prospective evaluation of a simple formula based on renal function | Q33429552 | ||
| Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. | Q34507119 | ||
| American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. | Q35613883 | ||
| Clinical implications of the mechanism of epidermal growth factor receptor inhibitors | Q36565941 | ||
| EGFR inhibitor-mediated apoptosis in solid tumors. | Q37014460 | ||
| The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. | Q40460294 | ||
| Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer | Q40493345 | ||
| ZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway | Q40593377 | ||
| Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. | Q40959114 | ||
| Cisplatin-induced activation of the EGF receptor | Q42807345 | ||
| Consolidation Docetaxel After Concurrent Chemoradiotherapy in Stage IIIB Non–Small-Cell Lung Cancer: Phase II Southwest Oncology Group Study S9504 | Q44438556 | ||
| Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. | Q46027726 | ||
| Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. | Q46672565 | ||
| Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer | Q46772387 | ||
| Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. | Q46942430 | ||
| Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. | Q51776233 | ||
| The epidermal growth factor receptor mediates radioresistance. | Q52011134 | ||
| Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide | Q57424604 | ||
| Combined Chemoradiotherapy Regimens of Paclitaxel and Carboplatin for Locally Advanced Non–Small-Cell Lung Cancer: A Randomized Phase II Locally Advanced Multi-Modality Protocol | Q61889869 | ||
| Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase acti | Q70218958 | ||
| One-sample multiple testing procedure for phase II clinical trials | Q70365924 | ||
| Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies | Q72856071 | ||
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lung cancer | Q47912 |
| chemoradiotherapy | Q5090613 | ||
| cetuximab | Q420296 | ||
| P304 | page(s) | 2312-2318 | |
| P577 | publication date | 2011-05-09 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324 | |
| P478 | volume | 29 |
| Q27014978 | 50 Years of progress in the systemic therapy of non-small cell lung cancer |
| Q37126741 | A Pilot Study (SWOG S0429) of Weekly Cetuximab and Chest Radiotherapy for Poor-Risk Stage III Non-Small Cell Lung Cancer |
| Q92067247 | A new standard of care for patients with surgically unresectable stage III non-small cell lung cancer |
| Q34041735 | A phase I study of concurrent individualized, isotoxic accelerated radiotherapy and cisplatin-vinorelbine-cetuximab in patients with stage III non-small-cell lung cancer |
| Q37716645 | A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer |
| Q37975010 | A review of clinical trials of cetuximab combined with radiotherapy for non-small cell lung cancer |
| Q35608002 | Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer |
| Q39156722 | Biological determinants of radioresistance and their remediation in pancreatic cancer |
| Q27329648 | Cetuximab Reconstitutes Pro-Inflammatory Cytokine Secretions and Tumor-Infiltrating Capabilities of sMICA-Inhibited NK Cells in HNSCC Tumor Spheroids |
| Q55013304 | Cetuximab in non-small-cell lung cancer |
| Q36989648 | Chemoradiation for definitive, preoperative, or postoperative therapy of locally advanced non-small cell lung cancer |
| Q24187972 | Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer |
| Q36993644 | Combined radio- and chemotherapy for non-small cell lung cancer: systematic review of landmark studies based on acquired citations |
| Q26852202 | Combining targeted agents and hypo- and hyper-fractionated radiotherapy in NSCLC |
| Q38176433 | Controversies in the management of stage III non-small-cell lung cancer |
| Q38549486 | Dose escalation for unresectable locally advanced non-small cell lung cancer: end of the line? |
| Q34216725 | EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: a secondary analysis of RTOG 0324. |
| Q37180302 | EGFR inhibition in non-small cell lung cancer: current evidence and future directions |
| Q38552978 | EGFR targeted therapies and radiation: Optimizing efficacy by appropriate drug scheduling and patient selection |
| Q34782417 | EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation |
| Q37661108 | ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition |
| Q36482508 | Effect of Radiation Therapy Techniques on Outcome in N3-positive IIIB Non-small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy |
| Q36143838 | Effects of selenomethionine on acute toxicities from concurrent chemoradiation for inoperable stage III non-small cell lung cancer |
| Q35538759 | Feasibility of cetuximab and chemoradiotherapy combination in Chinese patients with unresectable stage III non-small cell lung cancer: a preliminary report |
| Q35200424 | Following the crumbs: from tissue samples, to pharmacogenomics, to NSCLC therapy |
| Q39041541 | From chemotherapy to target therapies associated with radiation in the treatment of NSCLC: a durable marriage? |
| Q39510875 | Improved survival with dose-escalated radiotherapy in stage III non-small-cell lung cancer: analysis of the National Cancer Database. |
| Q34462689 | Influence of oral glutamine supplementation on survival outcomes of patients treated with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer |
| Q42783239 | Locally advanced and unresectable cutaneous squamous cell carcinoma: outcomes of concurrent cetuximab and radiotherapy |
| Q26767182 | Molecular targeted therapy to improve radiotherapeutic outcomes for non-small cell lung carcinoma |
| Q27025966 | Monoclonal antibodies for the treatment of cancer |
| Q38067454 | Monoclonal antibodies in lung cancer |
| Q33583931 | Multidisciplinary team approach for the management of patients with locally advanced non-small cell lung cancer: searching the evidence to guide the decision |
| Q38930358 | Multimodality Therapy for NSCLC. |
| Q50050377 | Nimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy for advanced non-small-cell lung cancer |
| Q34970294 | Nimotuzumab enhances the radiosensitivity of cancer cells in vitro by inhibiting radiation-induced DNA damage repair |
| Q39139857 | Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer |
| Q26827571 | Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer |
| Q26775388 | Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies |
| Q37069689 | Opportunities and challenges in the era of molecularly targeted agents and radiation therapy |
| Q36089579 | Personalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung Cancer |
| Q38400481 | Personalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitors |
| Q35051964 | Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors |
| Q36368864 | Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. |
| Q93112000 | Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08) |
| Q33720025 | Progress of clinical research on targeted therapy combined with thoracic radiotherapy for non-small-cell lung cancer |
| Q33711287 | Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinoma |
| Q50559529 | Quantification of CT-assessed radiation-induced lung damage in lung cancer patients treated with or without chemotherapy and cetuximab. |
| Q26765355 | Radio(chemo)therapy in locally advanced nonsmall cell lung cancer |
| Q38718558 | Randomized Phase II Study of Preoperative Chemoradiotherapy ± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non-Small Cell Lung Cancer: NRG Oncology RTOG 0839. |
| Q38155854 | Recent advances in radiotherapy for thoracic tumours |
| Q38047648 | Reversion of the ErbB malignant phenotype and the DNA damage response. |
| Q34061012 | SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus |
| Q35568485 | Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two facto |
| Q38390036 | State of the art of radiotherapy. |
| Q37028027 | TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR(+) head and neck cancer cells. |
| Q36999705 | Targeted therapies in non-small cell lung carcinoma: what have we achieved so far? |
| Q38815297 | Targeted therapy combined with radiotherapy in non-small-cell lung cancer: a review of the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society). |
| Q41339882 | Targeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer (NSCLC) to cytotoxic therapy: translational biology and rationale for current clinical trials |
| Q37642455 | Therapeutic management options for stage III non-small cell lung cancer |
Search more.